0001493152-23-002974.txt : 20230130
0001493152-23-002974.hdr.sgml : 20230130
20230130170104
ACCESSION NUMBER: 0001493152-23-002974
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230126
FILED AS OF DATE: 20230130
DATE AS OF CHANGE: 20230130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McNulty Christopher
CENTRAL INDEX KEY: 0001701459
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37769
FILM NUMBER: 23568704
MAIL ADDRESS:
STREET 1: C/O INVIVO THERAPEUTICS HOLDINGS CORP.
STREET 2: 1 KENDALL SQUARE, SUITE B14402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VBI Vaccines Inc/BC
CENTRAL INDEX KEY: 0000764195
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 160 SECOND STREET
STREET 2: CAMBRIDGE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-830-3031
MAIL ADDRESS:
STREET 1: 160 SECOND STREET
STREET 2: CAMBRIDGE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: SciVac Therapeutics Inc.
DATE OF NAME CHANGE: 20150717
FORMER COMPANY:
FORMER CONFORMED NAME: LEVON RESOURCES LTD.
DATE OF NAME CHANGE: 20100910
FORMER COMPANY:
FORMER CONFORMED NAME: LEVON RESOURCES LTD
DATE OF NAME CHANGE: 19850305
4
1
ownership.xml
X0306
4
2023-01-26
0
0000764195
VBI Vaccines Inc/BC
VBIV
0001701459
McNulty Christopher
C/O VBI VACCINES INC.,
160 SECOND STREET, FLOOR 3
CAMBRIDGE
MA
02142
1
1
0
0
CFO and Head of BD
Option (Right to Buy Common Shares)
0.575
2023-01-26
4
A
0
75000
0
A
2033-01-26
Common Shares
75000
75000
D
The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 26, 2023 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 26, 2023 (the "Option Agreement"). 25% of the options vest and become exercisable on the one-year anniversary of the Grant Date, with the remaining 75% of the options vesting and becoming exercisable in 24 equal monthly installments beginning on the first day of the month following the one-year anniversary of the Grant Date, subject to the reporting person's employment on the relevant vesting date.
The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement.
/s/ Christopher McNulty
2023-01-30